Romosozumab Pregnancy and Breastfeeding Warnings
Brand names: Evenity
Romosozumab Pregnancy Warnings
Not recommended
US FDA pregnancy category: Not assigned
Risk Summary: There are no data for use in pregnant women; in rats, a low incidence of skeletal malformations was observed.
Comments: This drug is not indicated for use in women of reproductive potential.
Weekly administration to pregnant rats during the period of organogenesis revealed skeletal abnormalities at exposures greater than 31 times the expected human exposure. Administration to rats prior to mating and through the end of lactation produced minimal to slight decrease in femoral bone mineral density and/or cortical circumferences in offspring at 1.4 to 54 times the expected human exposure. This drug is not indicated for use in women of reproductive potential. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Romosozumab Breastfeeding Warnings
Not recommended
Excreted into human milk: Unknown
Excreted into animal milk: Unknown
Comments:
This drug is not indicated for use in women of reproductive potential.
See also
References for pregnancy information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2019) "Product Information. Evenity (romosozumab)." Amgen USA
References for breastfeeding information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2019) "Product Information. Evenity (romosozumab)." Amgen USA
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.